Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.

Niels JongsGlenn M ChertowTom GreeneJohn J V McMurrayAnna Maria LangkildeRicardo Correa-RotterNaoki KashiharaEllen BurgessC David SjöströmBergur V Stefánsson Robert D TotoDavid C WheelerHiddo J Lambers Heerspinknull nullnull null

Published in: Journal of the American Society of Nephrology : JASN (2022)

Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression.<b>Clinical Trial registration number:</b> A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) NCT03036150.

Keyphrases

chronic kidney disease
liver failure
small cell lung cancer
clinical trial
epidermal growth factor receptor
respiratory failure
tyrosine kinase
drug induced
hepatitis b virus
risk factors
intensive care unit
open label
type diabetes
skeletal muscle
newly diagnosed
mechanical ventilation